【摘要】 目的探讨本院冠心病患者SLCO1B1和ABCB1基因多态性与脂溶性他汀类药物降脂作用的相关性。方法选取60例冠心病患者,通过荧光检测仪检测脂溶性他汀类药物代谢相关基因SLCO1B1*5(T>C)和ABCB1(2677T>G)的分布;患者每晚吞服辛伐他汀40 mg或阿托伐他汀20 mg,服药时间不少于4周,利用全自动生化检测仪检测服药前后血清胆固醇(TC)、三酰甘油(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)水平。结果 60例冠心病患者中,SLCO1B1*5(T>C)和ABCB1(2677T>G)突变频率分别为20%和65%,基因型分布均符合Hardy-Weinberg平衡;服药前后比较,携带SLCO1B1*5 TT、SLCO1B1*5 TC、ABCB1 2677 GG、ABCB1 2677 GT基因型患者的血清TC和LDL-C水平均显著降低。结论　SLCO1B1和ABCB1基因变异降低了他汀类药物的降脂强度,个体差异大。更多还原

【Abstract】 Objective To determine the correlation between the polymorphism of SLCO1B1 and ABCB1 genes and the lipid-lowering effect of fat-soluble statins in patients with coronary heart disease.Methods The distribution of fat-soluble statin-related metabolism genes SLCO1B1*5 (T>C) and ABCB1 (2677T>G) were detected in 60 patients with coronary heart disease by fluorescence detector.The patients were given 40 mg simvastatin or 20 mg atorvastatin every night for no less than 4 weeks.The serum cholesterol (TC),triglyceride (TG),high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) levels were detected before and after the drug administration with automatic biochemical analyzer.Results In the 60 patients with coronary heart disease,the mutation frequencies of SLCO1B1*5 (T>C) and ABCB1 (2677T>G) were 20% and 65%,respectively.The serum TC and LDL-C levels of the patients with SLCO1B1*5 TT,SLCO1B1*5 TC,ABCB1 2677 GG,and ABCB1 2677 GT genotypes were significantly lowered before and after the drug administration.Conclusion SLCO1B1 and ABCB1 gene mutations reduce the lipid-lowering intensity of statins with large individual differences.更多还原